


## SuO-Glu-Val-Cit-PAB-MMAE

<b>Cat. No.:</b>	HY-130989
<b>CAS No.:</b>	1895916-24-1
<b>Molecular Formula:</b>	C <sub>67</sub> H <sub>103</sub> N <sub>11</sub> O <sub>17</sub>
<b>Molecular Weight:</b>	1334.6
<b>Target:</b>	Drug-Linker Conjugates for ADC
<b>Pathway:</b>	Antibody-drug Conjugate/ADC Related
<b>Storage:</b>	-20°C, sealed storage, away from moisture and light * The compound is unstable in solutions, freshly prepared is recommended.



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 200 mg/mL (149.86 mM; ultrasonic and warming and heat to 60°C)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	0.7493 mL	3.7464 mL	7.4929 mL
	5 mM	0.1499 mL	0.7493 mL	1.4986 mL
	10 mM	0.0749 mL	0.3746 mL	0.7493 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

SuO-Glu-Val-Cit-PAB-MMAE consists a cleavable ADC linker (SuO-Glu-Val-Cit-PAB) and a potent tubulin inhibitor (MMAE). SuO-Glu-Val-Cit-PAB-MMAE can be used in the synthesis of antibody-drug conjugates (ADCs)<sup>[1]</sup>.

#### IC<sub>50</sub> & Target

Auristatin

#### In Vitro

ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker<sup>[1]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017 May;16(5):315-337.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA